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Introduction
The 2009 swine origin influenza A H1N1 (pH1N1) became the first influenza pandem-
ic in the 21st century. After the first case of illness reported in Mexico and the and the 
United States in March and April 2009, this infection spread rapidly and infected hu-
mans in over 70 countries within 3 months. The World Health Organization declared 
the pandemic alert level as phases 5-6 for pH1N1 [1]. The infection rates of pH1N1 dif-
fered among age groups, with most of infected patients younger than 25 years old. This 
may be because of the cross-protection of pre-existing antibodies in the elderly, par-
ticularly in those who had experienced other pandemic viruses [1,2].
 A diagnostic kit to test for pH1N1 was developed at the beginning of the outbreak. A 
rapid diagnostic tests using respiratory specimens for pH1N1 are commercially avail-
able. However, negative results in rapid diagnostic tests do not completely rule out in-
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Purpose: Enzyme-linked immunosorbent assay (ELISA) has been used in the diverse field 
to evaluate influenza virus infection; for the surveillance, diagnosis, efficacy evaluation, and 
development of the vaccine. The aim of this study was to establish an ELISA for detecting HA 
strain-specific antibodies using recombinant pandemic A H1N1 (pH1N1) HA1 (rHA1) protein. 
Materials and Methods: rHA1 was produced in baculovirus system. The clinical performance 
of the developed ELISA was validated using human serum samples, by comparison with stan-
dard methods for detecting a neutralizing antibody; hemagglutination inhibition (HI) assay and 
microneutralization test (MNT). The ability of the ELISA system to evaluate the efficacy test of 
an influenza vaccine was explored by measuring antibody levels in the serum of vaccinated 
mice.
Results: Our ELISA could detect anti-rHA1 antibody in influenza-infected patients and vac-
cinated subjects. Compared to HI assay and MNT as reference methods, our method showed 
good performance in detection of anti-rHA1 antibody. Detection of the anti-rHA1 antibody in 
vaccinated mice and its correlation with titers in HI assay was also proved in a mice model. 
Conclusion: An ELISA system using rHA1 of pH1N1 influenza virus was developed, and showed 
good clinical performance in diagnosis of influenza virus infection and evaluation of the vac-
cination efficacy in both human and animal models. 
Keywords: Influenza A virus, H1N1 subtype, Infection, Enzyme-linked immunosorbent assay, 
Vaccination
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fection with pH1N1. Typical serological tests can be used to 
detect r pH1N1 infection, such as hemagglutination inhibi-
tion (HI) assay or microneutralization test (MNT) [3,4]. Al-
though these traditional methods are sensitive, they are com-
plex and labor-intensive, thus a new active serological sur-
veillance method is required to detect influenza viruses as 
well as to evaluate antigenic match between circulating vi-
ruses and vaccine strains [4]. 
 In the present study, we developed and validated a hemag-
glutinin 1 (HA1)-specific enzyme-linked immunosorbent as-
say (ELISA) kit for serological detection of neutralizing anti-
bodies against pH1N1 using both human and mouse serum 
samples. This ELISA kit can be easily and quickly applied in 
any basic laboratory. The sensitivity and specificity for de-
tecting HA1 of influenza virus were also demonstrated, as 
compared to the traditional HI assays and MNT. This HA1-
specific ELISA kit could be a useful tool for detecting influen-
za virus outbreaks and determining vaccine efficacy. 
Materials and Methods
Production of recombinant H1N1 HA1 protein (rHA1)
Construction of recombinant plasmid 
The HA gene of influenza virus A/New York/3571/2009 (H1N1) 
was synthesizes based on the sequence in the NCBI Influenza 
Database, and the synthetic HA (residues 18-344) gene frag-
ment was amplified with adaptor primers having restriction 
enzyme sequences for BalII (forward) and XbaI (reverse) at 
the 5  ´end of each primer and then cloned into the 6x-His-tagg-
ed baculovirus transfer vector pAcGP67A (BD Bioscience, 
Franklin Lakes, NJ, USA). 
Production of rHA1
The recombinant transfer vector pAcGP67A and the Baculo-
Gold were co-transfected into Spodoptera frugiperda (SF9) 
insect cells according to the manufacturer’s instruction (BD 
Bioscience). A high-titer of recombinant virus was obtained 
from the cell-culture supernatant after two consecutive sub-
cultures. To obtain recombinant HA1 protein, High-Five cells 
(2×106 cells/mL) were infected with high-titer of recombinant 
virus at 27°C, 115 rpm for 3 days then cells were harvested 
and the recombinant proteins in the supernatant were ob-
tained by ammonium sulfate precipitation and Ni-NTA col-
umn purification (#1018, ADAR Biotech, Rehovot, Israel). The 
protein concentration was measured by bicinchoninic acid 
assay (Thermo Fisher Scientific, Waltham, MA, USA).
Western blotting
rHA1 was separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and the separated protein bands 
were visualized by Coomassie blue staining and silver stain-
ing. The proteins were transferred onto nitrocellulose mem-
branes (Bio-Rad, Hercules, CA, USA) and blocked with 5% 
skim milk in phosphate buffered saline (PBS) containing tween-20 
(PBST, 1× PBS and 0.05% Tween-20) for 1 hour at room tem-
perature (RT). The membrane was incubated with an anti-
HA1 mouse monoclonal antibody (1:1,000, ATGen, Seoul, 
Korea) in 0.2% bovine serum albumin (BSA) in PBST after 3 
washes with PBST at RT. The membranes were incubated at 
4°C overnight. Horseradish peroxidase (HRP)-conjugated 
goat anti-mouse antibody (1:3,000, Bio-Rad) as a secondary 
antibody in 5% skim milk-PBST was added after PBST wash-
ing and incubated for 1 hour at RT. After washing with PBST 3 
times, the membranes were developed using a chemilumini-
escent substrate (Amersham ECL, GE Healthcare, Bucking-
hamshire, UK) and exposing the protein side of the membrane 
to X-ray film.
Human serum samples
A total of 147 subjects was enrolled in this study. Forty-seven 
patients with influenza infection were confirmed by real-time 
polymerase chain reaction using nasopharyngeal swabs from 
patients with presenting fever. Blood samples from the pa-
tients were obtained at the time of H1N1 diagnosis. The con-
trol group of 30 subjects showed no flu-like symptoms or con-
firmed H1N1 infection. Samples from 70 subjects were col-
lected before vaccination (pre-vaccination) and resampled at 
4 weeks after vaccination with H1N1-inactivated influenza 
vaccine (post-vaccination). This study was approved by the 
Institutional Review Board Committee of Gangnam Sever-
ance Hospital (Seoul, Korea; IRB No. 3-2009-0170). Informed 
consents were obtained from all participants and all proce-
dures were carried out in accordance with the relevant guide-
lines and regulations.
HI assay 
The HI assay was performed as described previously [5]. Brief-
ly, sera were treated with receptor destroying enzyme at 30°C 
for 20 hours and inactivated at 56°C for 1 hour. The samples 
were serially diluted with PBS in the V-bottom 96-well plates 
then mixed with a standard amount of virus (4 HAU). The 
plates were incubated for 30 minutes at RT, and 0.5% of chick-
en red blood cells were loaded into each well and further in-
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cubated for 30 minutes at 25°C. The HI endpoint was the high-
est serum dilution at which agglutination was not observed. 
Microneutralization test 
Serum neutralizing antibody titers were determined by con-
ducting a multi-well plate cell culture assay. Briefly, MDCK 
cells were seeded at 1.5×10⁴ cells/well in a 96-well culture 
plate and cultured at 37°C, and 5% CO2 in an incubator to 
form a monolayer. Serially diluted samples pretreated with 
receptor destroying enzyme were mixed separately with 100 
TCID50 of A/New York/3571/2009 (H1N1) and incubated at 
37°C for 1 hour. The serum and virus mixture was added to 
the monolayer of MDCK cells. The plates were further incu-
bated for 18 hours at 37°C and washed with PBS 3 times, and 
fixed with 80% acetone for 10 minutes. The presence of viral 
proteins was confirmed by the monoclonal antibody against 
influenza nucleoprotein (NP), and the end point of the neu-
tralizing titer was determined as the highest serum dilution 
at which NP was reduced by 50%. 
Enzyme-linked immunosorbent assay 
Optimal dilutions of purified H1N1-rHA1 antigen were deter-
mined by various conditions and repeated experiments. For 
antigen coating, the indicated concentration of rHA1 anti-
gens (7.5 ng/mL) was diluted in cold carbonate buffer (pH 
9.6) in 96-well microplate and incubated at 4°C, overnight. 
Antigen-free carbonate the buffer was coated for endpoint 
assay and the background was subtracted. 3% of BSA in PBST 
was used for blocking (37°C for 1 hour). After washing the 
plate 5 times, serum samples were diluted and pre-incubated 
with blocking buffer containing supernatant of the High-Five 
cell culture medium (10 μg/mL of protein concentration) at 
RT for 10 minutes. Next, 100 μL of diluted serum samples 
(1:100) was applied in duplicate to each antigen-coated and 
non-coated well and incubated for 90 minutes at 37°C. After 
the plates were washed 5 times with PBST, HRP-conjugated 
rabbit anti-human IgG (1:10,000, Sigma-Aldrich, St. Louis, 
MO, USA) and anti-mouse IgG Ab (1:5,000, Santa Cruz Bio-
technology, Dallas, TX, USA) were added to each well match-
ing the sample origin. Next, the plates were incubated for 90 
minutes at 37°C and washed 7 times with PBST. For color de-
velopment, 100 μL of 3,3´,5,5´-tetra-methylbezidine in acidic 
buffer (KPL, Gaithersburg, MD, USA) was added to each well 
and incubated for 15 minutes at RT. The reaction was stopped 
by adding an equal volume of 2.5 N H2SO4. The optical densi-
ty (OD) was determined at a wavelength of 450 nm using a 
microplate reader within 30 minutes. Endpoint titers of hu-
man H1N1-HA1-specific Abs were expressed as the OD450 val-
ue of rHA1 uncoated well subtraction from rHA1-coated wells. 
Immunogenicity and protective efficacy in a murine model
Animals
Six-week-old female C57BL/6 mice were purchased from Ori-
ent Bio (Seoul, Korea). The animals were maintained in the 
animal care facilities of the Korea Research Institute of Bio-
science and Biotechnology (KRIBB) under specific pathogen-
free conditions. The experiments were approved by the Insti-
tutional Animal Care and Use Committee of KRIBB (KRIBB-
AEC-14058). 
Vaccination, sample collection, and viral challenge 
Each group of mice was immunized with 0.2, 0.5, or 0.8 μg of 
influenza virus A/California/04/2009 (CA04) vaccine candi-
date, suspended in a volume of 0.2 mL by intramuscular in-
jection twice at a 2-week interval. For the control experiment, 
0.2 mL of PBS was injected into the mice intramuscularly. Af-
ter 2 weeks after the last vaccination, the mice were anesthe-
tized with a Zoletil 50 mix (0.015 mL/20 g, Virbac Laboratory, 
Carros, France) and Rompun injection (0.5 mg/20 g, Bayer 
Korea, Seoul, Korea). Sera were collected by orbital bleeding. 
Next, the mice were challenged with 10× the LD50 of live in-
fluenza A virus in 30 μL of PBS into intranasal route. The body 
weight change and survival rate of the animals were also eval-
uated. 
Statistical analysis
All data were expressed as the mean±standard deviation. 
Statistical comparisons between experimental groups were 
performed using the Student’s t test. The sensitivity and spec-
ificity of ELISA for detecting the anti-HA1 specific antibody 
were reported by calculating the area under the receiving op-
erator characteristic curve. The correlation between the anti-
HA1 antibody and HI titer was determined by Pearson corre-
lation test. GraphPad Prism 8 (GraphPad Software Inc., La 
Jolla, CA, USA) was used for all analyses. p<0.05 was consid-
ered statistically significant. 
Results
Recombinant HA1 proteins were expressed in the baculovirus 
insect cell system
Recombinant H1N1-HA1-18-344 (rHA1) was expressed in 
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Fig. 1. Cloning and expression of recombinant HA1 proteins of pH1N1. (A) Synthetic HA1 gene sequence including restriction enzyme sites. (B) 
Sequences of the recombinant protein, HA1 gene of influenza virus A/ New York/3571/2009 (H1N1) was cloned into the 6×-His-tagged baculo-
virus transfer vector pAcGP67A. (C) rHA1 protein using baculovirus system was determined by Coomassie blue staining and silver staining after 
sodium dodecyl sulfate polyacrylamide gel electrophoresis. HA1, hemagglutinin 1; rHA1, recombinant H1N1 HA1 protein.
Fig. 1 Shim et al.
B
C
A
✓ Lane 1: HA1 (1 µg)
✓ Lane 2: High-Five cell culture soup (1 µg)
✓ Lane 3: HA1 (8.6 µg)
✓ Lane 4: High-Five cell culture soup (8.6 µg)
Coomassie blue 
staining
Silver 
staining
7
6
5
4
3
2
1
0
 M  1   2    3   4  M   1    2    3    4
C
B
A
kDa
Fig. 2. Validation of the ELISA system in human. (A, B) rHA1 protein could detect anti-HA1-specific antibody effectively both in patients with 
influenza virus infection (A) and after vaccination (B). (C) A table of diagnostic performance on the ELISA system, in comparison with HI assay 
and MNT. ***p<0.001, patients vs. controls (A), pre-vaccination vs. post-vaccination (B). ELISA, enzyme-linked immunosorbent assay; rHA1, 
recombinant H1N1 HA1 protein; HA1, hemagglutinin 1; HI, hemagglutination inhibition; MNT, microneutralization test; CI, confidence interval.
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the baculovirus insect system (Fig. 1A, B). Proteins were pro-
duced by High-Five cells after vector transformation. Purified 
rHA1 protein was confirmed by Coomassie blue and silver 
staining (Fig. 1C). H1N1 proteins of the expected size of 46 
kDa were isolated. 
The ELISA system using recombinant HA1 protein was  
established to detect anti-rHA1 antibody in patients with  
influenza virus infection 
The ELISA system using rHA1 protein was developed and 
validated to detect anti-rHA1 antibodies in the serum sam-
ples from influenza-infected patients and controls. According 
to this ELISA, OD values of patients were increased than con-
trols (0.942±0.371 vs. 0.212±0.086, p<0.001) (Fig. 2A). And in 
vaccinated individuals, anti-rHA1 antibody levels were sig-
nificantly increased after vaccination compared with levels 
from pre-vaccination status (Fig. 2B). From these data, this 
ELISA system using rHA1 could be useful in diagnosis of in-
fluenza infection and in discrimination of vaccination status 
in human. 
 The ELISA system was compared to standard detection 
methods for influenza virus infection, such as the HI assay 
and MNT. As shown in Fig. 2C, this ELISA system could be a 
sensitive and specific method for detecting the anti-rHA1 an-
Fig. 3. Measurements of anti-rHA1 antibodies in mice. (A) Experimental schedule of the vaccination and challenge in mice. (B, C) Body weight 
changes (B) and survival rate (C) in control and vaccinated mice after influenza virus infection. (D) The level of anti-rHA1 antibodies were mea-
sured by enzyme-linked immunosorbent assay in all groups of mice. (E) Anti-rHA1 antibodies were positively correlated with titers in HI assay 
(r=0.508, p<0.001). Black dots, PBS; gray dots, 0.2 μg; blue dots, 0.5 μg; red dots, 0.8 μg. rHA1, recombinant H1N1 hemagglutinin 1 protein; HI, 
hemagglutination inhibition; PBS, phosphate buffered saline; d.p.i., days post infection. (A) *p<0.05, ***p<0.001, compared to PBS group. 
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tibody in influenza-infected patients. The detection perfor-
mance of this ELISA system was comparable to that of the HI 
assay and MNT. 
Anti-rHA1 antibodies were detected by the ELISA system in 
the animal model of influenza virus infection 
The ELISA system using rHA1 protein was also validated in 
an animal model. The control (PBS) and vaccinated groups 
were compared. The vaccinated groups were immunized 
with influenza virus A/California/04/2009 (CA04) vaccine. 
The vaccines contained 3 different amounts of antigens, such 
as 0.2, 0.5, and 0.8 µg in each single dose of vaccine, respec-
tively. All mice were immunized with PBS or vaccines twice 
in 2 weeks apart and challenged at 2 weeks after the last vac-
cination (Fig. 3A). Body weight changes and the survival rate 
of vaccinated and non-vaccinated groups were monitored af-
ter influenza virus challenge (Fig. 3B, C). Compared to the 
control PBS group, the vaccinated groups showed lower body 
weight changes (Fig. 3B) and death rates (Fig. 3C). The serum 
levels of anti-rHA1 antibodies were measured in both non-
immunized and immunized mice by ELISA. The increased 
levels of antibodies were detected in all vaccinated mice but 
not in PBS group. The amount of antigens in vaccines did not 
affect the production of anti-rHA1 antibodies in this study 
(Fig. 3D). And the levels of anti-rHA1 antibodies were signifi-
cantly correlated with the results of HI assay using the same 
samples (r=0.508, p<0.001) (Fig. 3E). 
 Taken together, anti-rHA1 antibodies were detected by the 
ELISA system in vaccinated mice. The positive correlation 
between anti-rHA1 antibody measured by ELISA and titers in 
HI assay was also observed in the animal model. 
Discussion
A striking influenza pandemic occurred in 2009-2010. This 
highly pathogenic virus came from swine and the next pan-
demic virus has been thought to have arisen from avian sourc-
es in Asia [4]. Because of unpredictable and diverse sources, 
techniques for global surveillance in influenza virus infection 
that could be used both in humans and animals has been re-
quired. Humans have been exposed to influenza viruses that 
underwent antigenic and genetic changes; thus, assays that 
are strain-specific have been also required to characterize the 
viruses and detect immune responses to recent infection or 
vaccination [4]. The standard HI assay or MNT for measuring 
antibody responses to influenza virus surface antigens were 
developed previously [6,7]. Therefore, we focused on being 
strain-specific, convenient and readily available test for both 
humans and animals. 
 In this study, we produced recombinant HA1 influenza 
protein (2009 H1N1 pandemic strain) using a baculovirus-in-
sect cell system. We established the ELISA system using rHA1 
for detecting an anti-rHA1-specific antibody in humans, as 
well as in mice. Its clinical performance was also demonstrat-
ed by the comparison with those of HI assay and MNT. This 
ELISA system could be used for evaluating influenza virus 
vaccine efficacy, not even for diagnosing current infections. 
 Diagnostic techniques for early and accurate detection of 
newly emerging viruses are important for the rapid initiation 
of therapy and prophylaxis to control infection during disease 
outbreaks [6]. Traditional methods for detecting the neutral-
izing antibodies induced by influenza virus infection are time-
consuming and the results could be affected by several exter-
nal factors [4,8]. Rapid diagnostic kits for influenza viruses 
are commonly used to detect influenza infection. The results 
of rapid diagnostic kits could be completed within 30 min-
utes and are easily interpreted. However, rapid diagnostic kits 
showed lower sensitivity (62.3% reported in a meta-analysis) 
compared reverse transcription polymerase chain reaction‒
based approaches in the 2009 pandemic season. Accurate di-
agnosis of new emerging pathogen was limited at that time 
[6]. 
 In contrast, the ELISA system developed in this study, could 
be used to detect specific antibodies against certain strain of 
influenza virus in a short time. This method is relatively easy 
and convenient compared to the HI assay or MNT, with simi-
lar high sensitivity and specificity for diagnosis of influenza 
virus infection compared to the HI assay or MNT. Our meth-
od does not require a live virus to perform or complex proce-
dures. Moreover, this ELISA system could discriminate the 
vaccination status of the subjects, and thus the efficacy of vac-
cines could be also evaluated. 
 In summary, we established a recombinant HA1-based 
ELISA system for detecting anti-rHA1 antibody against influ-
enza virus infection in humans. We developed a diagnostic 
approach for influenza virus infection which showed good 
clinical performance. This method is also applicable for eval-
uating the vaccination status of the patients and efficacy of 
influenza virus vaccines. The ELISA system developed in this 
study is a useful approach for diagnosis of influenza virus in-
fection and assessment in vaccine efficacy. 
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